

Revision date 02-Apr-2025

Version 5.01

Page 1/19

Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

Product Name	Methylprednisolone Acetate Injectable Suspension, Single-Dose Vial
Product Code(s) Synonyms	PZ01044 PNU-8210
Trade Name:	DEPO-MEDROL; DEPO-NISOLONE; DEPO-MEDRONE; DEPO-MODERIN; DEPO-MEDOL; DEPO-MEDRATE
Item Code	H000400470,H000401047,H000401048,H000401071,H000401072,H000401073,H000401 074,H000401105,H000420001,H000420005,H000011490,H000011491,H000011873,H000 011874H000401242, H000401243, H000020331,H000020536,H000402477,H000402479,H000402968, H000402474
Chemical Family:	Glucocorticoid

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use

Pharmaceutical product used as anti-inflammatory

1.3. Details of the supplier of the safety data sheet

Pfizer Inc 66 Hudson Boulevard East		Pfizer Ireland Pharmaceuticals OSG Building
New York, New York 10001 1-800-879-3477		Ringaskiddy, Co. Cork. Ireland +353 21 4378701
E-mail address	pfizer-MSDS@pfizer.com	1000 21 4010101
1.4. Emergency telephone number	-	

Emergency Telephone

CHEMTREC (24 hours): 1-800-424-9300

Section 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture


GHS - Classification: Regulated according to Regulation (EC)1272/2008 and/or other applicable regulations.Reproductive toxicityCategory 1A- (H360D)Specific target organ toxicity (repeated exposure)Category 2- (H373)Hazardous to the aquatic environment - chronicCategory 2- (H411)

OSHA Classification

Hazards not otherwise classified (HNOC) Not applicable

Hazards classified under paragraph (d)(1)(ii) of 1910.1200 Not applicable

Product Name Methylprednisolone Acetate Injectable Suspension, Single-Dose Vial Revision date 02-Apr-2025



Other hazards	An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).
PBT & vPvB	The product does not contain any substance(s) classified as PBT or vPvB.
Endocrine Disruptor Information	This product does not contain any known or suspected endocrine disruptors.
Note:	This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances Substances

Not applicable

3.2 Mixtures

Hazardous

ſ	Chemical name	Weight-%	REACH	EC No (EU	Classification	Specific	M-Factor	M-Factor
			registration	Index No)	according to	concentration		(long-term)
			number		Regulation	limit (SCL)		

Product Name Methylprednisolone Acetate Injectable Suspension, Single-Dose Vial

Revision date 02-Apr-2025

				(EC) No.			
				1272/2008			
				[CLP]			
Methylprednisolone Acetate (CAS #: 53-36-1)	4-8		200-171-3	Repr.1A (H360D) STOT RE.2 (H373) Aquatic Acute	Not classified	No data available	1
				3 (H402) Aquatic Chronic 1 (H410)			
Myristyl-gamma-picoli nium chloride (CAS #: 2748-88-1)	<1.0		220-387-1	Acute Tox.3 (H301)	Not classified	No data available	No data available
Sodium hydroxide (CAS #: 1310-73-2)	**	-	215-185-5 (011-002-00-6)	Skin Corr.1A (H314)	Eye Irrit. 2 :: 0.5%<=C<2% Skin Corr. 1A :: C>=5% Skin Corr. 1B :: 2%<=C<5% Skin Irrit. 2 :: 0.5%<=C<2%	No data available	No data available
+ Hydrochloric Acid (CAS #: 7647-01-0)	**	-	231-595-7 (017-002-00-2) (017-002-01-X)		Eye Irrit. 2 :: 10%<=C<25% Skin Corr. 1B :: C>=25% Skin Irrit. 2 :: 10%<=C<25% STOT SE 3 :: C>=10%	No data available	No data available
NonHazardous					•		
Chemical name	Weight-%	REACH registration number	EC No (EU Index No)	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Water (CAS #: 7732-18-5)	*	-	231-791-2	Not classified	Not classified	No data available	No data available
Polyethylene glycol (CAS #: 25322-68-3)	*		Not Listed	Not classified	Not classified	No data available	No data available
SODIUM CHLORIDE (CAS #: 7647-14-5)	*	-	231-598-3	Not classified	Not classified	No data available	No data available
Sodium phosphate, monobasic (CAS #: 7558-80-7)	*		231-449-2	Not classified	Not classified	No data available	No data available
Sodium phosphate, dibasic (CAS #: 7558-79-4)	*		231-448-7	Not classified	Not classified	No data available	No data available

Full text of H- and EUH-phrases: see section 16

Acute Toxicity Estimate

Product Name Methylprednisolone Acetate Injectable Suspension, Single-Dose Vial Revision date 02-Apr-2025

·					
Chemical name	Oral LD50 mg/kg	Dermal LD50	Inhalation LC50 - 4	Inhalation LC50 - 4	Inhalation LC50 - 4
		mg/kg	hour - dust/mist - mg/L	hour - vapor - mg/L	hour - gas - ppm
Water 7732-18-5	89838.9	No data available	No data available	No data available	No data available
Methylprednisolone Acetate 53-36-1	10000	No data available	No data available	No data available	No data available
Polyethylene glycol 25322-68-3	22000	20000	No data available	No data available	No data available
SODIUM CHLORIDE 7647-14-5	3550	10000	No data available	No data available	No data available
Sodium phosphate, monobasic 7558-80-7	8290	7940	0.83	No data available	No data available
Sodium phosphate, dibasic 7558-79-4	17000	No data available	No data available	No data available	No data available
Myristyl-gamma-picoliniu m chloride 2748-88-1	250	No data available	No data available	No data available	No data available
Sodium hydroxide 1310-73-2	325	1350	No data available	No data available	No data available
+ Hydrochloric Acid 7647-01-0	238	5010	No data available	No data available	563.3022

This product does not contain candidate substances of very high concern at a concentration >=0.1% (Regulation (EC) No. 1907/2006 (REACH), Article 59).

Additional information

+ Substance with a Union workplace exposure limit

- * Proprietary
- ** to adjust pH

Non-hazardous ingredients provided for completeness. Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

Section 4: FIRST AID MEASURES

4.1. Description of first aid measures

Inhalation	Remove to fresh air. Seek immediate medical attention/advice.
Eye contact	Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.
Skin contact	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
Ingestion	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

4.2. Most important symptoms and effects, both acute and delayed

Product Name	Methylprednisolone Acetate Injectable Suspension,
Single-Dose Vi	al
Revision date	02-Apr-2025

Most important symptoms and effects	For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.				
4.3. Indication of any immediate me	dical attention and special treatment needed				
Note to physicians	None.				
Section 5: FIRE-FIGHTING M	EASURES				
5.1. Extinguishing media					
Suitable Extinguishing Media	Dry chemical, CO2, alcohol-resistant foam or water spray.				
5.2. Special hazards arising from th	e substance or mixture				
Specific hazards arising from the chemical	Fine particles (such as mists) may fuel fires/explosions.				
Hazardous combustion products	Formation of toxic gases is possible during heating or fire. May include oxides of carbon.				
Explosion data Sensitivity to mechanical impac Sensitivity to static discharge	t No information available. No information available.				
5.3. Advice for firefighters					
Special protective equipment and precautions for fire-fighters	Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.				
Section 6: ACCIDENTAL REL	EASE MEASURES				
6.1. Personal precautions, protectiv	e equipment and emergency procedures				
Personal precautions	Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.				
For emergency responders	Use personal protection recommended in Section 8.				
6.2. Environmental precautions					
Environmental precautions	Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.				
6.3. Methods and material for conta	inment and cleaning up				
Methods for containment Methods for cleaning up	Prevent further leakage or spillage if safe to do so. Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean				
Prevention of secondary hazards	 spill area thoroughly. Clean contaminated objects and areas thoroughly observing environmental regulations. 				
6.4. Reference to other sections					
Reference to other sections	See section 8 for more information. See section 13 for more information.				

Section 7: HANDLING AND STORAGE

Product Name Methylprednisolone Acetate Injectable Suspension, Single-Dose Vial Revision date 02-Apr-2025

7.1. Precautions for safe handling Advice on safe handling	Avoid breathing dust/fume/gas/mist/vapors/spray. Avoid contact with skin, eyes or clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.
General hygiene considerations	Handle in accordance with good industrial hygiene and safety practice.
7.2. Conditions for safe storage, inc Storage Conditions	cluding any incompatibilities Store as directed by product packaging.
7.3. Specific end use(s)	
Specific use(s)	Pharmaceutical drug product.

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control parameters

Exposure Limits	
Refer to available public information for specific member state	Dccupational Exposure Limits.
Methylprednisolone Acetate	
Pfizer OEL TWA-8 Hr: 40 µg/m ³	
Polyethylene glycol	
Austria	TWA-TMW: 1000 mg/m ³ ; inhalable fraction
	STEL-KZGW: 4000 mg/m ³ (4 X 15 min); inhalable fraction
Denmark	TWA: 1000 mg/m ³ ;
	STEL: 2000 mg/m ³ ;
Germany DFG	TWA-MAK: 250 mg/m ³ ; II(2);inhalable fraction
	Peak: 500 mg/m ³ ; inhalable fraction
Germany TRGS	TWA-AGW; 200 mg/m ³ (exposure factor 2); inhalable fraction
Russia	MAC: 10 mg/m ³
Slovakia	TWA: 1000 mg/m³;
Switzerland	TWA-MAK: 500 mg/m³;
SODIUM CHLORIDE	
Latvia	TWA: 5 mg/m³;
Russia	MAC: 5 mg/m ³
Sodium phosphate, monobasic	
Russia	MAC: 10 mg/m ³
Sodium phosphate, dibasic	
Russia	MAC: 10 mg/m ³
Sodium hydroxide	
ACGIH OEL (Ceiling)	2 mg/m ³
ACGIH TLV	Ceiling: 2 mg/m ³
Austria	TWA-TMW: 2 mg/m ³ ; inhalable fraction
	STEL-KZGW: 4 mg/m ³ (8 X 5 min); inhalable fraction
Bulgaria	TWA: 2.0 mg/m ³ ; alkaline aerosols
Czech Republic	1 mg/m ³
	Ceiling: 2 mg/m ³
Denmark	Ceiling: 2 mg/m ³ ;
Estonia	TWA: 1 mg/m ³ ;
	STEL: 2 mg/m ³ ;
Finland	Ceiling: 2 mg/m ³ ;

Product Name Methylprednisolone Acetate Injectable Suspension, Single-Dose Vial Revision date 02-Apr-2025

Page 7 / 19

Version 5.01

_	- / 2
France	2 mg/m^3
Hungary	TWA-AK: 1 mg/m ³ ;
	STEL-CK: 2 mg/m ³ ;
Ireland	STEL: 2 mg/m ³ ;
Ceiling Limit Value	2 mg/m ³
Latvia	TWA: 0.5 mg/m ³ ;
Poland	TWA-NDS: 0.5 mg/m ³ ;
	STEL-NDSCh: 1 mg/m ³ ;
Romania	TWA: 1 mg/m ³ ;
Kontania	STEL: 3 mg/m^3 ;
Slovakia	TWA: 2 mg/m ³ ;
Spain	STEL (VLA-EC): 2 mg/m ³ ;
Switzerland	TWA-MAK: 2 mg/m ³ ; inhalable dust
	STEL-KZGW: 2 mg/m ³ ; inhalable dust
OSHA PEL	TWA: 2 mg/m ³
	(vacated) Ceiling: 2 mg/m ³
United Kingdom	STEL: 2 mg/m ³ ;
+ Hydrochloric Acid	
ACGIH OEL (Ceiling)	2 ppm
ACGIH TLV	Ceiling: 2 ppm
Austria	TWA-TMW: 5 ppm;
	TWA-TMW: 8 mg/m ³ ;
	STEL-KZGW: 10 ppm (8 X 5 min);
	STEL-KZGW: 15 mg/m ³ (8 X 5 min);
Bulgaria	TWA: 5 ppm;
Daigana	TWA: 8.0 mg/m ³ ;
	STEL: 10 ppm;
Crach Depublic	STEL: 15.0 mg/m ³ ;
Czech Republic	8 mg/m ³
	Ceiling: 15 mg/m ³
Denmark	STEL: 5 ppm;
	STEL: 8 mg/m ³ ;
Estonia	TWA: 5 ppm;
	TWA: 8 mg/m³;
	STEL: 10 ppm;
	STEL: 15 mg/m ³ ;
European Union	TWA: 5 ppm;
	TWA: 8 mg/m ³ ;
	STEL: 10 ppm;
	STEL: 15 mg/m ³ ;
Finland	STEL: 5 ppm;
	STEL: 7.6 mg/m ³ ;
Germany DFG	TWA-MAK: 2 ppm; I(2);
	TWA-MAK: 3.0 mg/m ³ ; I(2);
	Peak: 4 ppm;
	Peak: 6 mg/m ³ ;
Germany TRGS	TWA-AGW; 2 ppm (exposure factor 2);
Germany TRG5	TWA-AGW; 2 ppm (exposure factor 2); TWA-AGW; 3 mg/m ³ (exposure factor 2);
Live see .	
Hungary	TWA-AK: 8 mg/m ³ ;
	TWA-AK: 5 ppm;
	STEL-CK: 165 mg/m ³ ;
	STEL-CK: 10 ppm;
Ireland	TWA: 8 mg/m ³ ;
	TWA: 5 ppm;
	STEL: 10 ppm;
	STEL: 15 mg/m ³ ;
Italy MDLPS	TWA: 5 ppm;
····, ···= =· -	· · · · · · · · · ·

Product Name Methylprednisolone Acetate Injectable Suspension, Single-Dose Vial Revision date 02-Apr-2025

Version 5.01

		TWA: 8 mg/m³;
		STEL: 10 ppm;
		STEL: 15 mg/m ³ ;
Ceiling Limit Value		2 ppm
		3.0 mg/m ³
Latvia		TWA: 5 ppm;
		TWA: 8 mg/m ³ ;
		STEL: 10 ppm;
		STEL: 15 mg/m ³ ;
Netherlands		TWA: 5 ppm;
		TWA: 8 mg/m³;
		STEL: 10 ppm;
		STEL: 15 mg/m ³ ;
Poland		TWA-NDS: 5 mg/m³;
		STEL-NDSCh: 10 mg/m ³ ;
Romania		TWA: 5 ppm;
		TWA: 8 mg/m³;
		STEL: 10 ppm;
		STEL: 15 mg/m ³ ;
Russia		MAC: 5 mg/m ³
Slovakia		TWA: 5 ppm;
		TWA: 8.0 mg/m³;
		Ceiling: 15 mg/m ³ ;
Spain		TWA-(VLA-ED): 5 ppm;
		TWA-(VLA-ED): 7.6 mg/m ³ ;
		STEL (VLA-EC): 10 ppm;
- · · ·		STEL (VLA-EC): 15 mg/m ³ ;
Switzerland		TWA-MAK: 2 ppm;
		TWA-MAK: 3 mg/m ³ ;
		STEL-KZGW: 4 ppm;
		STEL-KZGW: 6 mg/m ³ ;
U.S OSHA - Final PELs - Ceilin	g Limits	5 ppm
		7 mg/m ³
OSHA PEL		Ceiling: 5 ppm
		Ceiling: 7 mg/m ³
		(vacated) Ceiling: 5 ppm
		(vacated) Ceiling: 7 mg/m ³
United Kingdom		TWA: 1 ppm; gas and aerosol mist
		TWA: 2 mg/m ³ ; gas and aerosol mist
		STEL: 5 ppm; gas and aerosol mist
		STEL: 8 mg/m ³ ; gas and aerosol mist
Pfizor Occupational Exposure Ban		
Pfizer Occupational Exposure Band (OEB) Statement:		pational Exposure Band (OEB) classification system is to separate
(OED) Otatement.		Hazard categories when the available data are sufficient to do so,
		sh an Occupational Exposure Limit (OEL). The OEB given is based
		irrently available data; as such, this value may be subject to
		nation becomes available.
SODIUM CHLORIDE		
Pfizer Occupational Exposure	OEB 1 (control exposure	to the range of 1000ug/m ³ to 3000ug/m ³)
Band (OEB):	· ·	
Sodium phosphate, monobasic		
Pfizer Occupational Exposure	OEB 1 (control exposure	to the range of 1000ug/m ³ to 3000ug/m ³)
Band (OEB):		-
Sodium phosphate, dibasic		
Pfizer Occupational Exposure	OEB 1 (control exposure	to the range of 1000ug/m ³ to 3000ug/m ³)

Product Name Methylprednisolone Acetate Injectable Suspension, Single-Dose Vial Revision date 02-Apr-2025

Band (OEB):

Derived No Effect Level (DNEL) - Workers

Chemical name	Oral	Dermal	Inhalation
Polyethylene glycol 25322-68-3	-	112 mg/kg bw/day [4] [6]	40.2 mg/m ³ [4] [6]
SODIUM CHLORIDE 7647-14-5	-	295.52 mg/kg bw/day [4] [6] 295.52 mg/kg bw/day [4] [7]	2068.62 mg/m ³ [4] [6] 2068.62 mg/m ³ [4] [7]
+ Hydrochloric Acid 7647-01-0	-	-	8 mg/m³ [5] [6] 15 mg/m³ [5] [7]

Derived No Effect Level (DNEL) - General Public

Chemical name	Oral	Dermal	Inhalation
Polyethylene glycol 25322-68-3	40 mg/kg bw/day [4] [6]	-	7.14 mg/m ³ [4] [6]
SODIUM CHLORIDE	126.65 mg/kg bw/day [4] [6]	126.65 mg/kg bw/day [4] [6]	443.28 mg/m ³ [4] [6]
7647-14-5	126.65 mg/kg bw/day [4] [7]	126.65 mg/kg bw/day [4] [7]	443.28 mg/m ³ [4] [7]
+ Hydrochloric Acid	-	-	8 mg/m³ [5] [6]
7647-01-0			15 mg/m ³ [5] [7]

Predicted No Effect Concentration (PNEC)

Chemical name	Freshwater	Freshwater (intermittent release)	Marine water	Marine water (intermittent release)	Air
Polyethylene glycol 25322-68-3	0.273 g/L	1 mg/L	27.3 mg/L	0.1 mg/L	-
SODIUM CHLORIDE 7647-14-5	5 mg/L	-	-	-	-
Sodium phosphate, monobasic 7558-80-7	0.05 mg/L	0.5 mg/L	0.005 mg/L	-	-
Sodium phosphate, dibasic 7558-79-4	0.05 mg/L	0.5 mg/L	0.005 mg/L	-	-

Chemical name	Freshwater sediment	Marine sediment	Sewage treatment	Soil	Food chain
Polyethylene glycol 25322-68-3	1030 mg/kg sediment dw	103 mg/kg sediment dw	-	46.4 mg/kg soil dw	-
SODIUM CHLORIDE 7647-14-5	-	-	500 mg/L	4.86 mg/kg soil dw	-
Sodium phosphate, monobasic 7558-80-7	-	-	50 mg/L	-	-
Sodium phosphate, dibasic 7558-79-4	-	-	50 mg/L	-	-

Product Name Methylprednisolone Acetate Injectable Suspension, Single-Dose Vial Revision date 02-Apr-2025

Page 10/19

8.2. Exposure controls

Engineering controls Personal protective equipment	Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section. Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.
Eye/face protection	Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).
Hand protection	Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).
Skin and body protection	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).
Respiratory protection	Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.).
Thermal hazards	No information available.
Environmental exposure controls	No information available.

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties	
Appearance	suspension
Physical state	Liquid
Color	White
Odor	No information available.
Odor threshold	No information available
Property_	<u>Values</u>
Melting point / freezing point	No data available
Boiling point or initial boiling point and boiling range	No data available
Flammability (solid, gas)	No data available
Lower and upper explosion limit/flammability limit	
Lower explosion limit	No data available
Upper explosion limit	No data available
Flash point	No data available
Autoignition temperature	No data available
Decomposition temperature	

No data available 3.5 to 7.0

No data available

No data available

No data available No data available

No data available

No data available No data available

No data available

No data available

No information available

No information available

Product Name Methylprednisolone Acetate Injectable Suspension, Single-Dose Vial

Revision date 02-Apr-2025

Page 11/19

Version 5.01

SADT (°C)

pН pH (as aqueous solution) **Kinematic viscosity Dynamic viscosity** Solubility Vapor pressure Density and/or relative density Bulk density Liquid Density Vapor density Particle characteristics **Particle Size Particle Size Distribution**

Partition Coefficient: (Method, pH, Endpoint, Value) Myristyl-gamma-picolinium chloride Predicted 7.4 Log D 1.30 Methylprednisolone Predicted 7.4 Log D 1.99

9.2. Other information Molecular formula Molecular weight

Mixture Mixture

9.2.1. Information with regard to physical hazard classes No information available

9.2.2. Other safety characteristics No information available

Section 10: STABILITY AND REACTIVITY

10.1. Reactivity	
Reactivity	No information available.
10.2. Chemical stability	
Stability	Stable under normal conditions.
Explosion data	
Sensitivity to mechanical impact	
Sensitivity to static discharge	No information available.

10.3. Possibility of hazardous reactions Possibility of hazardous reactions No information available.

Hazardous polymerization 10.4. Conditions to avoid	Will not occur.
Conditions to avoid	Fine particles (such as dust and mists) may fuel fires/explosions.
<u>10.5. Incompatible materials</u> Incompatible materials	As a precautionary measure, keep away from strong oxidizers.

10.6. Hazardous decomposition products Hazardous decomposition products No data available.

Section 11: TOXICOLOGICAL INFORMATION

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

Product Name Methylprednisolone Acetate Injectable Suspension, Single-Dose Vial Revision date 02-Apr-2025

General Information:	ingredients The informatio	The information included in this section describes the potential hazards of the individual ingredients The information included in this section describes the potential hazards of various forms of the active ingredient.			
Short term Long Term:	Repeat-dose studies in an	May be harmful if absorbed through the skin. Repeat-dose studies in animals have shown a potential to cause adverse effects on developing forus and blood and blood forming organs.			
Known Clinical Effects:	Adverse clinical reactions leading to rashes, itching,	developing fetus and blood and blood forming organs Adverse clinical reactions include the development of hypersensitivity and/or irritation leading to rashes, itching, and burning. Clinical use has resulted in hormonal alterations. Clinical use has resulted in changes in electrolytes and/or blood chemistry changes.			
Acute toxicity Serious eye damage/eye irritati Skin corrosion/irritation Respiratory or skin sensitizatio STOT - single exposure STOT - repeated exposure	ion Based on available data, t Based on available data, t Based on available data, t Based on available data, t Based on available data, t May cause damage to org	Based on available data, the classification criteria are not met. Based on available data, the classification criteria are not met. Based on available data, the classification criteria are not met. Based on available data, the classification criteria are not met. Based on available data, the classification criteria are not met. Based on available data, the classification criteria are not met. May cause damage to organs through prolonged or repeated exposure. Classification is based on mixture calculation methods based on component data.			
Reproductive toxicity			ixture calculation methods based		
Germ cell mutagenicity Carcinogenicity Aspiration hazard	Based on available data, t	he classification criteria are not n he classification criteria are not n he classification criteria are not n	net.		
Acute Toxicity: (Species, Route, End Point, Dose) Methylprednisolone Acetate Rat Oral LD50 >10,000 mg/kg Mouse Sub-tenon injection (eye) LD50 >1,409 mg/kg Rat Subcutaneous LD50 265 mg/kg SODIUM CHLORIDE Rat Sub-tenon injection (eye) LC50/1hr > 42 g/m ³ Rat Oral LD 50 3 g/kg Mouse Oral LD 50 4 g/kg Rabbit Dermal LD 50 > 10 g/kg Myristyl-gamma-picolinium chloride Rat Oral LD 50 250 mg/kg Rat Intraperitoneal LD50 7500 ug/kg Rat Subcutaneous LD50 200 mg/kg Mouse IP LD50 40 mg/kg Methylprednisolone Rat Oral LD 50 > 2000 mg/kg Mouse IP LD50 40 mg/kg Methylprednisolone Rat Oral LD 50 > 2000 mg/kg Mouse IP LD50 40 mg/kg Mouse IP LD50 50 1000 mg/kg Mouse Oral LD 50 > 2000 mg/kg Mouse Oral LD 50 > 1000 mg/kg Mouse ID LD 50 1000 mg/kg					
Rat Subcutaneous LD 50 > Chemical name	3000 mg/kg Oral LD50	Dermal LD50	Inhalation LC50		
Water	> 90 mL/kg (Rat)	-	-		
Methylprednisolone Acetate	> 10 g/kg (Rat)	-	-		
Polyethylene glycol	= 22 g/kg (Rat)	> 20 g/kg (Rabbit)	-		

> 10000 mg/kg (Rabbit)

> 42 mg/L (Rat) 1 h

= 3550 mg/kg (Rat)

SODIUM CHLORIDE

Product Name Methylprednisolone Acetate Injectable Suspension, Single-Dose Vial Revision date 02-Apr-2025

Sodium phosphate, monobasic	= 8290 mg/kg (Rat)	> 7940 mg/kg (Rabbit)	> 0.83 mg/L (Rat)4 h
Sodium phosphate, dibasic	= 17 g/kg (Rat)	-	-
Myristyl-gamma-picolinium chloride	= 250 mg/kg (Rat)	-	-
Sodium hydroxide	= 325 mg/kg (Rat)	= 1350 mg/kg (Rabbit)	-
+ Hydrochloric Acid	238 - 277 mg/kg (Rat)	> 5010 mg/kg (Rabbit)	= 1.68 mg/L (Rat)1 h

Acute Toxicity Comments:

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Unknown acute toxicity

4-8 % of the mixture consists of ingredient(s) of unknown acute dermal toxicity.

4-8 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (dust/mist).

Irritation / Sensitization: (Study Type, Species, Severity)

MethylprednisoloneAcetateEye IrritationRabbitNo effectSkin IrritationRabbitNo effectPolyethyleneglycolEye IrritationRabbitMildSkin IrritationRabbitMild

SODIUM CHLORIDE

 Skin irritation
 Rabbit
 Mild

 Eye irritation
 Rabbit
 Mild

 + Hydrochloric Acid
 Skin irritation
 Severe

 Eye irritation
 Severe
 Severe

 Sodium hydroxide
 Eye Irritation
 Rabbit

 Eye Irritation
 Rabbit
 Severe

 Skin Irritation
 Rabbit
 Severe

 Methylprednisolone
 Skin irritation
 Rabbit

 Skin irritation
 Rabbit
 No effect

 Eye irritation
 Rabbit
 No effect

 Skin Sensitization - GPMT
 Guinea Pig
 No effect

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Myristyl-gamma-picolinium chloride60 Day(s)RatOral2400mg/kgDeathMethylprednisolone42 Day(s)DogOral167µg/kg/dayLOAELAdrenal gland6 Week(s)RatSubcutaneous500µg/kg/dayLOAELNone identified14 Week(s)RatSubcutaneous0.4µg/kg/dayNOAELBlood forming organs, Adrenal gland52 Week(s)RatSubcutaneous4µg/kg/dayNOAELBlood forming organs, Adrenal gland

<u>Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))</u> <u>Methylprednisolone</u>

Reproductive & Fertility Rat Subcutaneous 0.004 mg/kg/day NOAEL Paternal toxicity Reproductive & Fertility Rat Subcutaneous 0.02 mg/kg/day LOAEL Fetotoxicity Embryo / Fetal Development Rat Subcutaneous 1.0 mg/kg/day LOAEL Fetotoxicity, Teratogenic Embryo / Fetal Development Mouse Intramuscular 330 mg/kg/day LOAEL Teratogenic Embryo / Fetal Development Rabbit Intramuscular 0.1 mg/kg/day LOAEL Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Product Name Methylprednisolone Acetate Injectable Suspension, Single-Dose Vial Revision date 02-Apr-2025 Page 14/19

Version 5.01

Methylprednisolone Acetate Direct DNA Interaction Not applicable In Vitro Cytogenetics Not applicable + Hydrochloric Acid	0
Bacterial Mutagenicity (Ames) Salme In Vivo Micronucleus Rat Negative	
Methylprednisolone	
Bacterial Mutagenicity (Ames) Salm	5
Unscheduled DNA Synthesis Rat Her Mammalian Cell Mutagenicity Chines Direct DNA Interaction Negative	patocyte Negative e Hamster Ovary (CHO) cells Negative
Carcinogenicity	None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.
+ Hydrochloric Acid IARC	Group 3

 11.2. Information on other hazards

 11.2.1. Endocrine disrupting properties

 Endocrine disrupting properties

 Based on available data, the classification criteria are not met.

11.2.2. Other information	
Other adverse effects	No information available.

Section 12: ECOLOGICAL INFORMATION

```
Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be avoided. Toxic to aquatic life with long lasting effects. Classification is based on mixture calculation methods based on component data.
```

12.1. Toxicity

Aquatic Toxicity: (Species, Method, End Point, Duration, Result) Methylprednisolone Daphnia magna (Water Flea) N/A EC50 48 hours > 85 mg/L Daphnia magna (Water Flea) N/A NOEC 48 hours 85 mg/L Ceriodaphnia dubia (Daphnids) N/A EC50 48 hours 19 mg/L Ceriodaphnia dubia (Daphnids) N/A EC10 48 hours 6.1 mg/L Pseudokirchneriella subcapitata (Green Alga) N/A NOEC 96 hours 160 mg/L Chronic Aquatic Toxicity: (Species, Method, Duration, Endpoint, Result, Adverse Endpoint) Methylprednisolone Ceriodaphnia dubia (Daphnids) N/A 7 Day(s) EC50 0.23 mg/L Ceriodaphnia dubia (Daphnids) N/A 32 Day(s) EC10 0.031 mg/L Reproduction Ceriodaphnia dubia (Daphnids) N/A 32 Day(s) EC50 0.294 mg/L Reproduction

12.2. Persistence and degradability

Persistence and degradability No information available.

12.3. Bioaccumulative potential

Bioaccumulation

Product Name Methylprednisolone Acetate Injectable Suspension, Single-Dose Vial Revision date 02-Apr-2025 Page 15/19

Partition Coefficient: (Method, pH, Endpoint, Value)

Myristyl-gamma-picolinium chloride Predicted 7.4 Log D 1.30 Methylprednisolone Predicted 7.4 Log D 1.99

12.4. Mobility in soil

Mobility in soil

No information available.

12.5. Results of PBT and vPvB assessment

PBT and vPvB assessment

Based on available data, the classification criteria are not met.

Chemical name	PBT and vPvB assessment
Polyethylene glycol	Not PBT/vPvB
SODIUM CHLORIDE	Not PBT/vPvB PBT assessment does not apply
Sodium phosphate, monobasic	PBT assessment does not apply
Sodium phosphate, dibasic	PBT assessment does not apply
+ Hydrochloric Acid	Not PBT/vPvB PBT assessment does not apply
Sodium hydroxide	Not PBT/vPvB PBT assessment does not apply

12.6. Endocrine disrupting properties

Endocrine disrupting properties	Based on available data, the classification criteria are not met.
---------------------------------	---

12.7. Other adverse effects	
Other adverse effects	No information available.
PMT or vPvM properties	Based on available data, the classification criteria are not met.

Section 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods

Waste from residues/unused products

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

This material is regulated for transport as a hazardous material/dangerous good under IMDG, ADR, IATA but not under DOT.

UN number:	UN 3077
UN proper shipping name:	Environmentally Hazardous Substance, Solid, n.o.s (Methylprednisolone Acetate)

Product Name Methylprednisolone Acetate Injectable Suspension, Single-Dose Vial Revision date 02-Apr-2025

Transport hazard class(es):	9
Packing group:	III
Environmental Hazard(s):	Marine Pollutant

5 kg/5L Exception:

UN3082 and UN3077 materials contained in good quality packaging in the quantities listed below are not subject to the dangerous goods transportation regulations by any mode:

* Single packagings containing a net quantity of 5 liters or less for liquids or a net mass of 5 kg or less for solids.

* Combination packagings containing a net quantity per inner packaging of 5 liters or less for liquids or a net mass of 5 kg or less for solids.

Section 15: REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Water	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	231-791-2
AICS	Present
Methylprednisolone Acetate	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS	200-171-3
Polyethylene glycol	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	Not Listed
AICS	Present
Standard for Uniform Scheduling of Medicines and	Schedule 3
Poisons (SUSMP)	Schedule 2
SODIUM CHLORIDE	
	Nie til Sete al
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
California Proposition 65 TSCA	Not Listed Present
California Proposition 65 TSCA EINECS	Not Listed Present 231-598-3
California Proposition 65 TSCA EINECS AICS	Not Listed Present
California Proposition 65 TSCA EINECS AICS Sodium phosphate, monobasic	Not Listed Present 231-598-3 Present
California Proposition 65 TSCA EINECS AICS Sodium phosphate, monobasic CERCLA/SARA Section 313 de minimus %	Not Listed Present 231-598-3 Present Not Listed
California Proposition 65 TSCA EINECS AICS Sodium phosphate, monobasic CERCLA/SARA Section 313 de minimus % California Proposition 65	Not Listed Present 231-598-3 Present Not Listed Not Listed
California Proposition 65 TSCA EINECS AICS Sodium phosphate, monobasic CERCLA/SARA Section 313 de minimus % California Proposition 65 TSCA	Not Listed Present 231-598-3 Present Not Listed Not Listed Present
California Proposition 65 TSCA EINECS AICS Sodium phosphate, monobasic CERCLA/SARA Section 313 de minimus % California Proposition 65 TSCA EINECS	Not Listed Present 231-598-3 Present Not Listed Not Listed Present 231-449-2
California Proposition 65 TSCA EINECS AICS Sodium phosphate, monobasic CERCLA/SARA Section 313 de minimus % California Proposition 65 TSCA EINECS AICS	Not Listed Present 231-598-3 Present Not Listed Not Listed Present
California Proposition 65 TSCA EINECS AICS Sodium phosphate, monobasic CERCLA/SARA Section 313 de minimus % California Proposition 65 TSCA EINECS AICS Sodium phosphate, dibasic	Not Listed Present 231-598-3 Present Not Listed Not Listed Present 231-449-2 Present
California Proposition 65 TSCA EINECS AICS Sodium phosphate, monobasic CERCLA/SARA Section 313 de minimus % California Proposition 65 TSCA EINECS AICS Sodium phosphate, dibasic CERCLA/SARA Section 313 de minimus %	Not Listed Present 231-598-3 Present Not Listed Present 231-449-2 Present Not Listed
California Proposition 65 TSCA EINECS AICS Sodium phosphate, monobasic CERCLA/SARA Section 313 de minimus % California Proposition 65 TSCA EINECS AICS Sodium phosphate, dibasic CERCLA/SARA Section 313 de minimus % Hazardous Substances RQs	Not Listed Present 231-598-3 Present Not Listed Present 231-449-2 Present Not Listed 5000 lb
California Proposition 65 TSCA EINECS AICS Sodium phosphate, monobasic CERCLA/SARA Section 313 de minimus % California Proposition 65 TSCA EINECS AICS Sodium phosphate, dibasic CERCLA/SARA Section 313 de minimus % Hazardous Substances RQs California Proposition 65	Not Listed Present 231-598-3 Present Not Listed Present 231-449-2 Present Not Listed 5000 lb Not Listed
California Proposition 65 TSCA EINECS AICS Sodium phosphate, monobasic CERCLA/SARA Section 313 de minimus % California Proposition 65 TSCA EINECS AICS Sodium phosphate, dibasic CERCLA/SARA Section 313 de minimus % Hazardous Substances RQs California Proposition 65 TSCA	Not Listed Present 231-598-3 Present Not Listed Present 231-449-2 Present Not Listed 5000 lb Not Listed Present
California Proposition 65 TSCA EINECS AICS Sodium phosphate, monobasic CERCLA/SARA Section 313 de minimus % California Proposition 65 TSCA EINECS AICS Sodium phosphate, dibasic CERCLA/SARA Section 313 de minimus % Hazardous Substances RQs California Proposition 65	Not Listed Present 231-598-3 Present Not Listed Present 231-449-2 Present Not Listed 5000 lb Not Listed

Product Name Methylprednisolone Acetate Injectable Suspension, Single-Dose Vial

Revision date 02-Apr-2025

Standard for Uniform Scheduling of Medicines and Poisons (SUSMP) Myristyl-gamma-picolinium chloride	Schedule 5 Schedule 6
CERCLA/SARA Section 313 de minimus % California Proposition 65 TSCA EINECS AICS Sodium hydroxide	Not Listed Not Listed Present 220-387-1 Present
CERCLA/SARA Section 313 de minimus % Hazardous Substances RQs California Proposition 65 TSCA EINECS AICS Standard for Uniform Scheduling of Medicines and Poisons (SUSMP) + Hydrochloric Acid	Not Listed 1000 lb Not Listed Present 215-185-5 Present Schedule 5 Schedule 6
CERCLA/SARA Section 313 de minimus % Hazardous Substances RQs California Proposition 65 TSCA EINECS AICS Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	1.0 % 5000 lb Not Listed Present 231-595-7 Present Schedule 5 Schedule 6

National regulations

France

Occupational Illnesses (R-463-3, France)

Chemical name	French RG number
SODIUM CHLORIDE	RG 78
7647-14-5	

Germany

Chemical Prohibition Ordinance (ChemVerbotsV) Not applicable

TRGS 905

Not applicable

Switzerland

Ordinance on the Incentive Tax on Volatile Organic Compounds (OVOC) SR 814.018	Not applicable
Storage of Hazardous Material	Not applicable
WPO (GSchV) SR 814.201; WPA (GSchG) SR 814.20	Not applicable
Major Accidents Ordinance SR 814.012	Not applicable

European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work.

Authorizations and/or restrictions on use:

This product contains one or more substance(s) subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Chemical name	Restricted substance per REACH	Substance subject to authorization per
	Annex XVII	REACH Annex XIV
Sodium hydroxide	75	-

Product Name Methylprednisolone Acetate Injectable Suspension, Single-Dose Vial

Revision date 02-Apr-2025

1310-73-2		
+ Hydrochloric Acid	75	-
7647-01-0		

Persistent Organic Pollutants

Not applicable

Named dangerous substances per Seveso Directive (2012/18/EU)

Chemical name	Lower-tier requirements (tons)	Upper-tier requirements (tons)
+ Hydrochloric Acid	25	250
7647-01-0		

Ozone-depleting substances (ODS) Regulation (EU) 2024/590 Not applicable.

EU - Plant Protection Products (1107/2009/EC)

Chemical name	EU - Plant Protection Products (1107/2009/EC)
SODIUM CHLORIDE	Plant protection agent
7647-14-5	

Biocidal Products Regulation (EU) No 528/2012 (BPR)

Chemical name	Biocidal Products Regulation (EU) No 528/2012 (BPR)
SODIUM CHLORIDE	Product-type 1: Human hygiene
7647-14-5	
+ Hydrochloric Acid	Product-type 2: Disinfectants and algaecides not intended
7647-01-0	for direct application to humans or animals

Explosives Precursors Marketing and Use (2019/1148)

Not applicable

Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

DSL/NDSL - Canadian Domestic Substances List/Non-Domestic Substances List

EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

ENCS - Japan Existing and New Chemical Substances

IECSC - China Inventory of Existing Chemical Substances

KECL - Korean Existing Chemicals Inventory

PICCS - Philippines Inventory of Chemicals and Chemical Substances

AICS - Australian Inventory of Chemical Substances

NZIOC - New Zealand Inventory of Chemicals

TCSI - Taiwan Chemical Substance Inventory

15.2. Chemical safety assessment

No information available Chemical Safety Report

Section 16: OTHER INFORMATION

Key or legend to abbreviations and acronyms used in the safety data sheet

Full text of any hazard and/or precautionary statements referred to under Sections 2-15

H360D - May damage the unborn child. H373 - May cause damage to organs through prolonged or repeated exposure if

Product Name Methylprednisolone Acetate Injectable Suspension, Single-Dose Vial Revision date 02-Apr-2025

swallowed. H301 - Toxic if swallowed. H335 - May cause respiratory irritation. H314 - Causes severe skin burns and eye damage. H331 - Toxic if inhaled. H410 - Very toxic to aquatic life with long lasting effects. H402 - Harmful to aquatic life.

Classification procedure Calculation method	
Data Sources:	Pfizer proprietary drug development information. Safety data sheets for individual ingredients. Publicly available toxicity information.
Reason for revision	Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological Information. Updated Section 15 - Regulatory Information.
Revision date	02-Apr-2025
Prepared By	Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.